thiazoles has been researched along with Keratoacanthoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bility, MT; Gonzalez, FJ; Kang, BH; Peters, JM; Zhu, B | 1 |
| Berretta, S; Buscarino, C; Del Fabro, V; Di Raimondo, F; Giallongo, C; Massimino, M; Messina, A; Pennisi, MS; Restuccia, N; Stagno, F; Stella, S; Tibullo, D; Tirrò, E; Vigneri, P | 1 |
2 other study(ies) available for thiazoles and Keratoacanthoma
| Article | Year |
|---|---|
Ligand activation of peroxisome proliferator-activated receptor-beta/delta and inhibition of cyclooxygenase-2 enhances inhibition of skin tumorigenesis.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anticarcinogenic Agents; Carcinoma, Squamous Cell; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Models, Animal; Female; Keratinocytes; Keratins; Keratoacanthoma; Ligands; Mice; Mice, Inbred C57BL; Mice, Knockout; Papilloma; PPAR delta; PPAR-beta; RNA, Messenger; Skin Neoplasms; Sulfonamides; Thiazoles; Time Factors | 2010 |
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Dasatinib; Ear Diseases; Fusion Proteins, bcr-abl; Humans; Keratoacanthoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Second Primary; Pyrimidines; Radiotherapy; Scalp; Thiazoles; Tongue Neoplasms; Vocal Cords | 2010 |